Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Peer power: could support groups boost HIV prevention in transgender men?

NCT ID NCT06182280

Prevention Sponsor: Fenway Community Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Sep 17, 2026 · Updated 3 times

Summary

This study tests whether peer-led support—either one-on-one, in a group, or both—can help transgender men who have sex with men start and continue taking PrEP, a daily pill that prevents HIV. Participants are randomly assigned to receive standard HIV prevention information, a tailored one-on-one program, a peer-group program, or both. The goal is to see if these personalized support approaches increase PrEP use and persistence compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Peer support interventions (one-on-one and group-based) tailored for transgender masculine people, compared with standard HIV prevention information.
What this could lead to
If effective, these peer-led programs could become a practical way to increase PrEP use and reduce HIV rates among transgender men who have sex with men.
What could go wrong
The trial is relatively small and early, so results may not apply broadly. Also, the interventions rely on peer engagement, which may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 or over * Identifies as a man, trans man, or another transmasculine identity * Has had sex with a partner assigned male sex at birth with a flesh penis in the last 3 months * Has access to a smartphone or computer with internet access * Is HIV-uninfected * Resides in one of the Ending the Epidemic targeted geographic hotspots in the United States * Willing and able to provide informed consent in English * Meets CDC guidelines for PrEP indications in the last 3 months (adapted for TMSM) including: * Condomless receptive vaginal/frontal or anal sex with a partner assigned male at birth with a flesh penis * Sharing needles or syringes for illicit drug use and/or hormones * Self-reported anogenital sexually transmitted infection diagnosis Exclusion Criteria: * Less than age 18 * Does not identify as a man, trans man, or another transmasculine identity * Does not have access to a smartphone or computer * Is living with HIV (HIV positive) * Does not reside in one of the Ending the Epidemic geographic hotspots in the United States * Will not or cannot provide written informed consent in English * Does not meet the trans-adapted CDC guidelines for PrEP indications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adherence, medication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Homosexuality Medication Adherence HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adherence, medication HIV infections

Contacts and locations

Locations

  • Fenway Health

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.